ReviewAmerican journal of translational research2020
The potential therapeutic role of
Review in American journal of translational research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.
- Altered molecular signature of the intestinal microbiota in irritable bowel syndrome patients versus healthy controls: An updated systematic review.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2026Pooled it
- The efficacy of lactobacillus reuteri in conjunction with racecadotril in managing pediatric rotavirus enteritis and its impact on intestinal mucosa and immune function.African health sciences · 2025Trial
- Impact of chronic consumption of probiotics, oats, and apples on expression of genes related to bile acids, lipid, gut peptides, and inflammation in peripheral monocular cells - findings from the CABALA study.European journal of nutrition · 2025Trial
- Alteration of the Gut-Lung Axis After Severe COVID-19 Infection and Modulation Through Probiotics: A Randomized, Controlled Pilot Study.Nutrients · 2024Trial
- Targeting the Gut Microbiota with Pro- and Postbiotics: Emerging Strategies against Alopecia.Probiotics and antimicrobial proteins · 2026Review
- An Experimental Design to Evaluate the Effects of Process and Formulation on the Viability and Efficacy of L. reuteri Enteric-Coated Pellets in a Rat Model with Colitis.Probiotics and antimicrobial proteins · 2026Article
- Limosilactobacillus reuteri SXDT-32-derived shikimic acid protects against colonic inflammation in piglets by inhibiting the PI3K-Akt pathway.Journal of animal science and biotechnology · 2025Article
- Probiogenomic analysis ofHeliyon · 2025Article
- Real-world of Limosilactobacillus reuteri in mitigation of acute experimental colitis.Journal of nanobiotechnology · 2025Article
- Microbiota composition-based donor selection affects FMT efficacy in a murine colitis model.Frontiers in immunology · 2025Article
- Evaluating the Therapeutic Efficacy ofCurrent pharmaceutical design · 2025Review
- Protective effect of a newly probiotic Lactobacillus reuteri LY2-2 on DSS-induced colitis.European journal of nutrition · 2024Article
- Article
- Development of a novel complex inflammatory bowel disease mouse model: Reproducing human inflammatory bowel disease etiologies in mice.PloS one · 2024Article
- From-Toilet-to-Freezer: A Review on Requirements for an Automatic Protocol to Collect and Store Human Fecal Samples for Research Purposes.Biomedicines · 2023Review
- Research on Pachymaran to Ameliorate CsA-Induced Immunosuppressive Lung Injury by Regulating Microflora Metabolism.Microorganisms · 2023Article
- Edible exosome-like nanoparticles from portulaca oleracea L mitigate DSS-induced colitis via facilitating double-positive CD4Journal of nanobiotechnology · 2023Article
- Oral Administration ofMicroorganisms · 2023Article
- In Vitro Effect of the Cell-Free Supernatant of theMicroorganisms · 2023Article
- Preparation and Evaluation of a Dosage Form for Individualized Administration of Lyophilized Probiotics.Pharmaceutics · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel disease (IBD) is a chronic intestinal disease of unknown etiology. However, recent studies have established a pathological role of disordered intestinal microbiota and immune dysregulation. Clinical studies have suggested that the reconstruction of the normal intestinal flora in patients with IBD can reverse the dysbiosis caused by genetic, environmental, dietary, or antibiotic factors to ameliorate the symptoms of IBD.
Indexed as
Identifiers
32509162PMC7270012W3033912849What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.